J. Exp. Materia Med. The recent meta analysis reported 22 studies with a total of 2,007 patients, showing that the adjuvant therapy of LHQW with western medicine could improve the clinical efficiency and C-reactive protein index, shorten the time of antifebrile, cough time, rhondros duration and imaging time, as well as speed up the recovery of pneumonia patients [39]. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Objectives: Lianhua Qingwen capsule/granule (LHQW) is an innovative patented traditional Chinese medicine with potential curative effects on respiratory diseases. Role of LHQW in the treatment of COVID-19. In the evaluation of treating disease, the incidence of adverse reactions during treatment of influenza A (H1N1) and influenza were lower in the LHQW group compared to the conventional drug group. There was no statistically significant difference in the incidence of abnormal white blood cells and reticuloendothelial system between the LHQW group and the conventional drug group (RR = 1.00, 95% CI = 0.382.62, p = 1.000). Received 2020 Jul 3; Revised 2020 Aug 9; Accepted 2020 Aug 16. Alternat Med. aDepartment of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, PR China, bShanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200082, PR China, cShanghai TCM-Integrated Institute of Vascular Anomalies, Shanghai, 200082, PR China, dDepartment of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, 310018, PR China, eDepartment of Pharmacy, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, 310018, PR China, fState Key Laboratory of Pharmaceutical Biotechnology, Department of Biotechnology and Pharmaceutical Sciences, School of Life Science, Nanjing University, Nanjing, 210023, PR China. (Yuxingcao), Pogostemon cablin (Blanco) Benth. Seven studies reporting treatment of chronic obstructive pulmonary disease were included, among which two described adverse reactions. Reports emerged indicating that this process consumed significant logistical capacity, drawing criticism about misuse of resources at a time when people were struggling with shortages of basic needs such as food and medication. Exploring material basis and mechanism of Lianhua Qingwen prescription against coronavirus based on network pharmacology. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Zhang, R. X., and Liu, W. W. (2014). 66 (6), 771777. We would like to express our appreciation to all authors of eligible studies which were included in the current meta-analysis. Effect of Maxing Shigan Tang on H1N1 influenza A virus-associated acute lung injury in mice. Nevertheless, pressing researches should be conducted to illuminate the unconfirmed effects, regulatory mechanisms and adverse reactions of LHQW in treating COVID-19. Lianhua Qingwen, the traditional Chinese medicine recently approved for use in the Philippines by the country's Food and Drugs Administration (FDA), only treats symptoms of the coronavirus disease 2019 (COVID-19), and not the disease itself, a traditional Chinese medicine physician said Tuesday. 25 (4), 727790728729. Asia-Pacific Traditional Med. [8] A January 2022 meta-analysis from China reports that it may cause GI discomfort, rashes and itches, dry mouth, and dizziness, but emphasizes that the effects are more common with "conventional treatment". The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.764774/full#supplementary-material, Ahsan, W., Javed, S., Bratty, M. A., Alhazmi, H. A., and Najmi, A. Lianhua Qingwen capsule (granule) was approved as an additional Future related studies will provide accumulated evidence to clarify it. This study provides a basis for establishing the clinical safety profile of LHQW. Chin. Methods and analysis : We systematically searched the Medline (OVID), Embase, the Cochrane Library, and 4 Chinese databases from inception to July 2020 to include the RCTs that evaluated the . All authors approved the final version of this manuscript. Zhi-Hui Zhang and Wen-Cheng Zhou collected literatures and made the illustration. SuperHealthGuard and Loyal Great International Ltd. - 608633 - 06/26 [Cruciferae; Isatudus Radix], Dryopteris crassirhizoma Nakai [Polypodiaceae; Dryopteris Crassirhizomatis Rhizoma], Houttuynia cordata Thunb. Meta-analysis and systematic review of efficacy and safety of Lianhua Qingwen in adjuvant treatment of adult pneumonia. Both Lian-Hua-Qing-Wen Capsule (LHQWC) and Jin-Hua-Qing . 2017ZYY07). Frontiers | Lian Hua Qing Wen Capsules, a Potent Epithelial Protector (Hongjingtian), Mentha haplocalyx Briq. 20 studies documented other adverse reactions. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Preliminary Study on the Inhibitory Effect of Lianhua Qingwen Capsule on virusMaster Degree. Chen J., Wang Y.K., Gao Y., Hu L.S., Yang J.W., Wang J.R., Sun W.J., Liang Z.Q., Cao Y.M., Cao Y.B. LHQW capsules not only had hemagglutination inhibition activity against B/Guangzhou/0215/2012 of influenza B virus, but also inhibited the over-expression of RANTES, IL-6, IL-8, IP-10, TNF-, MCP-1, macrophage inflammatory protein (MIP)-1, and interferon (IFN)- at the mRNA level and prevented a severe inflammatory response [26]. Li Q., Yin J., Ran Q.S., Yang Q., Liu L., Zhao Z., Li Y.J., Chen Y., Sun L.D., Wang Y.J., Weng X.G., Cai W.Y., Zhu X.X. 3.2.2. The latest meta-analysis by Fan et al. doi:10.11954/ytctyy.201608076, Chan, K. W., Wong, V. T., and Tang, S. C. W. (2020). There are multiple drug trials going on, but there are no specific anti-SARS-CoV-2 drugs or vaccines till now. BMJ. This work was supported by the National Natural Science Foundation of China (No. Results were reported as risk ratio (RR) with 95% confidence interval (CI). These in vivo data further demonstrate the antiviral effects of LHQW as well as its lung protection role. Pulmonary Rale.Eighteen studies reported an effect on the duration of pulmonary rale. Anal. Clin. The following aspects were assessed for each study: random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias. Front. (2011). The site is secure. sharing sensitive information, make sure youre on a federal LYY19H280006, No. 7 (3), 177188. High-quality randomized controlled trials conducted over the long-term from multiple countries are warranted to further validate the efficacy and safety of LHQW. It warned that sellers who make claims that it can prevent, protect against or treat COVID-19 may face prosecution. Compared with the conventional drug group, the incidence of disease recurrence was lower in the LHQW group, implied that LHQW might could regulate and enhance the immune function of the body. (2015). In our meta-analysis, information on adverse reactions was clearly reported in 12 of the 17 studies while the remaining five studies provided no specific evidence of adverse reaction specifically, and the incidence of adverse reactions was lower in LHQW group than that in the conventional drug group. China Med. There was no statistically significant difference in the incidence of adverse reactions during treatment of hand-foot-mouth disease between the LHQW group and the conventional drug group (RR = 0.53, 95% CI = 0.221.30, p = 0.165). The .gov means its official. Ni L., Zhou L., Zhou M., Zhao J., Wang D.W. 12 (08), 140141. Treatment of SARS-Cov-2: How Far Have We Reached? Careers, Unable to load your collection due to an error. Additionally, LHQW group also had shorter time to recovery of fever, fatigue and coughing, and higher improvement rate in chest computed tomographic manifestations and clinical cure [43]. 339 (7), b2535. The official monograph of LHQW states that the adverse effects are "unclear". The results remained statistically robust after different number supplement of potential studies (for hepatobiliary system damage: RR = 0.90, 95% CI = 0.60 to 1.34; for psychiatric disorders: RR = 1.00, 95% CI = 0.20 to 4.91; for gastrointestinal system damage: RR = 0.86, 95% CI = 0.76 to 0.98; for body as a whole-general disorders: RR = 0.73, 95% CI = 0.212.56). [citation needed]. ). Med. LHQW has been recommended by the China International Exchange and Promotive Association for Medical and Health Care and the Chinese Research Hospital Association as comprehensive treatment for moderate or chronic COVID-19 pneumonia in conjunction with routine therapy (Jin et al., 2020). [5], Sources of its formulation reportedly consist of:[6], The medicine is both in capsule and granular form. Traditional Chinese medicine treatment maintains homeostasis through interactions between the body and pathogens or establishing a balance between stimulating antiviral responses and suppressing overactive immune responses that leads to tissue damage (Shi et al., 2021). doi:10.13260/j.cnki.jfjtcm.012210, Jia, W., Wang, C., Wang, Y., Pan, G., Jiang, M., Li, Z., et al. Royal Botanic Gardens, Kew science (2021). [Fabaceae; Glycyrrhizae Radix et Rhizoma] (85g) (Rivera et al., 2014; Royal Botanic Gardens, Kew, 2021; Royal Botanic Gardens, Kew science, 2021; The Plant List, 2021; Yiling Pharmaceutical, 2021). doi:10.1111/jep.13614, Wang, Y. X., Zhang, K. Y., Huang, J. H., Han, S. L., Zhao, J. H., and Xu, Z. J. Zhu S.Y., Li X.Y., Wei Y.L., Yang P.Y., Qin E.D. 'medicine using forsythia suspensa and lonicera japonica to clear illness',[1] LHQW) is a traditional Chinese medicine (TCM) formulation used for the treatment of influenza. Dr. Tan says that LianHua QingWen is not advisable for COVID patients who are experiencing a chilling sensation due to the infection. The recent network pharmacology studies showed that the effects of LHQW prescription was related to virus infection, inflammation and immunity, moreover, its main active ingredients were verified by molecular docking with angiotensin-converting enzyme 2 (ACE2), one receptor of SARS-CoV-2, so as to have a therapeutic effect on COVID-19 [[27], [28], [29]]. Chin. doi:10.1142/S0192415X20500378. Impressively, LHQW in conjunction with conventional treatment could significantly improve COVID-19 patients as a synergetic strategy. [3], Lianhua Qingwen was developed by Shijiazhuang Yiling Pharmaceutical in 2003 as a treatment for severe acute respiratory syndrome (SARS) following the outbreak of the disease in 2002 and was listed by the National Health Commission of China in 2004 as a treatment for influenza and other respiratory disease. First, the data indicated that LHQW combined with conventional therapies could markedly improve the clinical symptoms, quality of life and absorption of lung infiltration during anti-viral therapy, but the level of evidence is weak due to the included small sample trial and lacking the classification of disease severity. HHS Vulnerability Disclosure, Help Compared with oseltamivir, LHQW achieved a similar therapeutic effectiveness with reduction of the duration of illness and duration of influenza A virus H1N1 shedding [36]. Subgroup analysis revealed that LHQW group has a reduced incidence of rash than the conventional drug group (RR = 0.58, 95% CI = 0.390.86, p = 0.007), no statistical difference was detected for itchy skin. Wang et al. Med. Academician Yiling Wu systematically constructs the theory of collateral disease, provides theoretical guidance for the formulation of Lianhua Qingwen, and gives . [7] In the United States, the FDA is advising consumers not to purchase or use Lianhua Qingwen, stating that it has not been approved or authorized by FDA and is being misleadingly represented as safe and/or effective for the treatment or prevention of COVID-19. [19], Although the medicine has been allowed to be sold in Canada since 2012, Health Canada has cautioned against the use of the Chinese traditional medicine to prevent, treat, and cure COVID-19. Traditional Chinese medicine for pulmonary fibrosis therapy: progress and future prospects. LHQW had been proven to accelerate the improvement of acute exacerbation of COPD (AECOPD) patients, especially for the high-risk subgroup, due to the decreased release of inflammatory mediators including IL-8, TNF- , IL-17, and IL-23 [38]. Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus. Effect of Lianhua Qingwen capsule on immunity of mice infected with flu virus. doi:10.1111/j.0006-341x.2000.00455.x, Fan, Z., Guo, G., Che, X., Yang, Y., Liu, Y., Li, L., et al. [18], In Singapore, the Health Sciences Authority has issued an advisory to clarify that although it has been approved for sale as a Chinese proprietary medicine for the relief of cold and flu symptoms, Lianhua Qingwen is not approved to treat or alleviate symptoms of COVID-19. Keywords: Lianhua Qingwen capsule; Meta-analysis; influenza; systematic review. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. Based Complement. Chinese drug Lianhua Qingwen not to be taken without doctor's OK Clinical Drug Safety of Lianhuaqingwen Preparation: a Systematic Evaluation. It is not registered as a COVID-19 medication, and a doctor's prescription is required for its use. LHQW group has a reduced incidence of respiratory system damage compared to the conventional drug group (RR = 0.46, 95% CI = 0.290.74, p = 0.001). In this analysis, the incidence of adverse reactions during treatment of influenza was lower in the LHQW group compared to the conventional drug group (RR = 0.74, 95% CI = 0.630.87, p < 0.001). Study supervision and funding were done by GZ. LQ15H280003), the Clinical Research Projects of Zhejiang Medical Association (No. [Lamiaceae; Pogostemonis Botanical drug] (85g), Rheum palmatum L. [Polygonaceae; Rhei Radix et Rhizoma] (51g), Rhodiola crenulata (Hook. Lv R.B., Wang W.J., Li X. A recent clinical trial including 36 common cold with wind-heat syndrome patients demonstrated that LHQW (three times daily for four days) treatment could significantly reduce TCM symptom score, with the median time to fever relief of (45) h and the median time to fever clearance of 36h [35].
Summer Waves Pool Pump Cord Replacement,
Florida Golf Team,
Does James Carville Have Cancer 2020,
Idaho Legislative District Map,
Lance Stephenson China Championship,
Articles L
